How much funding has TRIMTECH Therapeutics raised?

TRIMTECH Therapeutics has raised $45.0M in total funding, most recently a seed round.

When was TRIMTECH Therapeutics founded?

TRIMTECH Therapeutics was founded in 2023.

Where is TRIMTECH Therapeutics headquartered?

TRIMTECH Therapeutics is headquartered in Cambridge, United States.

What industry is TRIMTECH Therapeutics in?

TRIMTECH Therapeutics operates in Biotech.

How many employees does TRIMTECH Therapeutics have?

TRIMTECH Therapeutics has 1-10 employees.

TRIMTECH Therapeutics

Q: Who are TRIMTECH Therapeutics's investors?

TRIMTECH Therapeutics's investors include Cambridge Innovation Capital, SV Health Investors, Johnson & Johnson Innovation.

First-in-class medicines for cost-effective, disease-modifying neurodegeneration treatment.

Cambridge, United States · Founded 2023 · $45.0M raised

Biotech

Headquarters: Cambridge
Employees: 1–10
Founded: 2023
Business Model: B2B

Website: trimtechtherapeutics.com
Total Funding: $45.0M
Last Round: $14.0M SeedJun 2026
Rounds: 2

About

TRIMTECH Therapeutics develops targeted protein degraders called TRIMTACs and TRIMGLUEs designed to selectively eliminate toxic protein aggregates in CNS and inflammatory conditions. The platform is grounded in research into TRIM21, an underutilized ubiquitin ligase, enabling a differentiated approach to treating diseases driven by protein aggregation.

Summary

TRIMTECH Therapeutics is a Biotech company based in Cambridge, United States, founded in 2023. It has raised $45.0M in total across 2 rounds, most recently a $14.0M Seed round in Jun 2026. Investors include Cambridge Innovation Capital, SV Health Investors and Johnson & Johnson Innovation.